FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
Anticoagulation in obese patients: challenges and strategies
2029PDF: 530HTML: 303XML: 186 -
The key to fibrinolysis and thrombolysis
1692PDF: 523HTML: 261 -
Diagnostic and management practices for inherited fibrinogen disorders: a nationwide survey of Italian Hemophilia Treatment Centers
920PDF: 119HTML: 122Supplementary: 79Appendix: 79 -
The landscape of rare coagulation factor deficiency management in Italy: a national hemophilia center survey
1350PDF: 218HTML: 133Appendix: 119 -
CO091 | DOWNREGULATION OF MARKERS OF PLATELET ACTIVATION, PLATELET TURNOVER, AND PLATELET DESIALYLATION IN GOOD RESPONDERS TO FIRST-LINE TREATMENT(S) FOR IMMUNE THROMBOCYTOPENIA B. Clerici1|2, C. Ghali2, M. Scavone2, A. Fioretti2, E.G. Bossi2, S. Birocchi1, E. Tarasconi1|2, G. D'Avanzo1, M. Carpenedo3, S. Caberlon2, G.M. Podda1|2 | 1.S.C. Medicina Generale SP, Ospedale San Paolo, ASST Santi Paolo e Carlo, Milano, Italy; 2Dipartimento di Scienze della Salute (DISS), Università degli Studi di Milano, Italy; 3S.S. Ematologia Non Oncologica, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy. B. Clerici and C. Ghali contributed as co-first authors
8PDF: 2 -
Still unmet problems with low molecular weight heparin prophylaxis of venous thromboembolism. An Italian survey
1445PDF: 305HTML: 202Supplementary: 102 -
PO34 | INVESTIGATORS’ DECISIONS ON ANTICOAGULATION AFTER EXTENDED API-CAT TREATMENT FOR CANCER VENOUS THROMBOEMBOLISM I. Mahé1|4, F. Happe2, M. Monreal5|7, H. Robert-Ebadi8, P. Debourdeau9, J. R. Fabreguettes10, S. Accassat11, P. Mismetti4|11|12, P. Girard13, S. Laporte4|12|14, C. Chapelle14 | 1Paris Cité University; 2Assistance Publique - Hôpitaux de Paris, Louis Mourier Hospital, Department of Internal Medicine; 3Inserm UMR-S970, Paris Cardiovascular Research Center, Team « Endotheliopathy and Hemostasis Disorders », Paris, France; 4F-CRIN INNOVTE Network, France; 5Department of Internal Medicine, Institut de Recerca Germans Trias i Pujol, Hospital Universitari Germans Trias i Pujol, Badalona, Spain; 6Department of Medicine, Universitat Autonoma de Barcelona, Barcelona; 7Universidad Catolica San Antonio de Murcia, Murcia, Spain; 8Division of Angiology and Hemostasis, Faculty of Medicine, Geneva University Hospitals, Geneva, Switzerland; 9Arles Hospital, Oncology unit, Arles, France; 10Assistance Publique - Hôpitaux de Paris, AGEPS, France; 11Service de Médecine Vasculaire et Therapeutique, CHU de Saint-Etienne, Saint-Etienne, France; 12Université Jean Monnet, Mines Saint-Étienne, INSERM Unité 1059, Santé Ingénierie Biologie Saint-Étienne SAINBIOSE, Saint-Étienne, France; 13Département de Pneumologie, Institut Mutualiste Montsouris, Paris; 14Service de Pharmacologie Clinique, CHU de Saint-Etienne, Saint-Etienne, France
423PDF: 90 -
PO44 | Emicizumab in acquired haemophilia A M. Leotta, A. Strangio, A. Ierardi, S. Prejanò, R C. Santoro | Hemostasis and Thrombosis Unit, Department Hemato-Oncology, Azienda Ospedaliero-Universitaria Renato; Dulbecco, Catanzaro, Italy
619PDF: 20 -
CO092 | FOSTAMATINIB IN CHRONIC IMMUNE THROMBOCYTOPENIA: A REAL-WORLD MONOCENTRIC EXPERIENCE M. Biglietto, S. Sorella, S. Ligia, S. Santostefano, R. Celia, R. Mormile, E. Baldacci, A. Chistolini, C. Santoro | Sapienza University of Roma, Italy
9PDF: 2 -
PO091 | RESPONSE AND CARDIOVASCULAR SAFETY OF FOSTAMATINIB IN CHRONIC IMMUNE THROMBOCYTOPENIA: A REAL WORLD ANALYSIS C. Giubbilei, G. Giustini, A. Baffioni, V. Carrai | SOD Ematologia, Azienda Universitaria Ospedaliera Careggi, Firenze, Italy
7PDF: 2 -
PO155 | MANAGEMENT OF ANTICOAGULANT THERAPY IN IMMUNOTHROMBOSIS SECONDARY TO TOXOPLASMA INFECTION A. Grembiale1, A. Sabena1, G. Dettori1, C. Grendene1, S. Grazioli1, S. Venturini2 | 1SOC Medicina Interna 2 - Azienda Sanitaria Friuli Occidentale - Pordenone, Italy; 2SSD Malattie Infettive - Azienda Sanitaria Friuli Occidentale - Pordenone, Italy
8PDF: 2 -
CO094 | ASSESSMENT OF THE MINIMAL EFFECTIVE DOSE OF AVATROMBOPAG IN IMMUNE THROMBOCYTOPENIA: A SINGLE-CENTER REAL-WORLD STUDY A. Baffioni1, C. Giubbilei1, G. Giustini1, A.M. Vannucchi2, V. Carrai3 | 1SOD Ematologia, Università degli studi di Firenze, Italy; 2Center for Innovation and Research in Myeloproliferative Neoplasms, SOD Ematologia, Azienda Ospedaliera Universitaria Careggi, Università degli studi di Firenze, Italy; 3SOD Ematologia, Dipartimento di Oncologia, Azienda Ospedaliera Universitaria Careggi, Firenze, Italy
5PDF: 2 -
PO156 | DIRECT ORAL ANTICOAGULANTS FOR THE TREATMENT OF VTE IN PATIENTS WITH CANCER: A SURVEY AMONG CAMPANIAN INTERNAL MEDICINE WARDS E. Marrone1, C. Arturo2, F. Cannavacciulo3, D. D’Ambrosio4, F. Gallucci1, M. Amitrano3, C. Di Gennaro2, P. Morella1, A. Maffettone5 | 1UOC Medicina 3, AORN A Cardarelli, Napoli, Italy; 2UOC Medicina Generale, PO A. Rizzoli, Ischia, Italy; 3UOC Medicina Interna, AO Moscati, Avellino, Italy; 4UOC Medicina Generale, PO Piedimonte Matese ASL Caserta, Italy; 5UOC Medicina interna, PO San Luca, Vallo Della Lucania ASL Salerno, Italy
5PDF: 2 -
PO50 | Treatment with BTK inhibitors in patients affected by chronic lymphocytic leukemia: safety and hemostasis L. Gurgoglione, C.A. Piro, I. Scortechini, I. Battilà, M.C. Merlo, A. R. Scortechini, S. Rupoli, A. Poloni | Hematology Unit, AOU delle Marche-Università Politecnica delle Marche, Italy
516PDF: 14 -
PO46 | Intravitreal treatment with faricimab in patients with age-related macular degeneration M. Alfonsetti1, R. Liani1, P.G.M. Simeone1, M. Frezza1, A. Ricci3, S. Lattanzio1, R. D’Aloisio2, L. Toto2, F. Santilli1 | 1Department of Medicine and Aging, Center for Advanced Studies and Technology “CAST”; 2Ophthalmology Clinic, Department of Medicine and Aging; 3Department of Pharmacy, University “G. d’Annunzio” of Chieti Pescara, Chieti, Italy
476PDF: 15 -
PO089 | A RISK-ADAPTED, MULTIDISCIPLINARY CONSENSUS FOR ADULT ITP MANAGEMENT: BRIDGING GUIDELINES AND REAL-WORLD PRACTICE A. Votto1, E. Pacini2, G. Giustini3, I. Rina1, S. Galimberti1 | 1Department of Clinical and Experimental Medicine, University of Pisa, Italy; 2Hematology Unit, University of Siena, Azienda Ospedaliera Universitaria Senese, Italy; 3Hematology Unit, AOU Careggi, Firenze, Italy
6PDF: 2 -
PO005 | EXTENDED ANTICOAGULATION WITH DOACS IN PATIENTS AFFECTED BY HEMATOLOGIC MALIGNANCIES AND VENOUS THROMBOEMBOLISM: DOES LOW DOSE FIT ALL? M. Biglietto, S. Sorella, L.V. Cappelli, B. Mandelli, D. Kasmi, E. Baldacci, A. Chistolini | Sapienza University of Roma, Italy
2PDF: 2 -
CO-50 | LEFT ATRIAL APPENDAGE OCCLUSION IN PATIENTS WITH ATRIAL FIBRILLATION AND BLEEDING DISORDERS: A SINGLE-CENTER EXPERIENCE B.M. Roccon1, M.I. Tassoni1, G. Quintavalle1, G. Benatti2, F. Gurgoglione2, R. Rossi3, C. Cattabiani3, L. Vignali2, A. Tagliaferri1, A. Coppola1 | 1SSD Centro Hub Emofilia e Malattie Emorragiche Congenite, Azienda Ospedaliero-Universitaria di Parma, Italy; 2SSD Cardiologia Interventistica, Azienda Ospedaliero-Universitaria di Parma, Italy; 3Laboratorio di Coagulazione, UOC Patologia Clinica, Azienda Ospedaliero-Universitaria di Parma, Italy
33PDF: 16 -
PO028 | SUSTAINED RESPONSE OFF TREATMENT IN ITP PATIENTS TREATED WITH TPO-RA: A SINGLE-CENTER EXPERIENCE A. Baffioni1, C. Giubbilei1, G. Giustini1, A.M. Vannucchi2, V. Carrai3 | 1SOD Ematologia, Università degli studi di Firenze, Italy; 2Center for Innovation and Research in Myeloproliferative Neoplasms, SOD Ematologia, Azienda Ospedaliera Universitaria Careggi, Università degli studi di Firenze, Italy; 3SOD Ematologia, Dipartimento di Oncologia, Azienda Ospedaliera Universitaria Careggi. Firenze, Italy
5PDF: 2 -
PO28 | Long term effectiveness and safety of venous thromboembolism with fondaparinux: data from the start registry I.M. Palumbo1, E. Valeriani1,2, A. Pannunzio1, S. Marucci3, D. Menichelli1, D. Pastori3,4, P. Pignatelli3 | 1Department of General Surgery and Surgical Specialty, Sapienza University of Roma; 2Department of Infectious Disease, Azienda Ospedaliero-Universitaria Policlinico Umberto I, Roma; 3Department of Clinical Internal, Anaesthesiologic and Cardiovascular Sciences, Sapienza University of Roma, Roma; 4IRCCS NeuRomad, Pozzilli, Italy
634PDF: 12 -
PO59 | Efficacy and safety of different anticoagulant treatment regimens for isolated internal jugular vein thrombosis: a case series A. Pannunzio1, E. Valeriani1, I.M. Palumbo1, S. Marucci2, D. Menichelli1, D. Pastori2, P. Pignatelli2 | 1Department of General Surgery and Surgical Specialty, Sapienza University of Roma; 2Department of Clinical, Internal Medicine, Anaesthesiological and Cardiovascular Sciences, Sapienza University of Roma, Italy
691PDF: 31 -
CO012 | LONG-TERM RISK OF RECURRENT VENOUS THROMBOEMBOLISM IN ADULT PATIENTS WITH ACTIVE CANCER AND FIRST CATHETER-RELATED UPPER EXTREMITY DEEP VEIN THROMBOSIS AFTER DISCONTINUATION OF ANTICOAGULANT TREATMENTS AND LINE REMOVAL: A RETROSPECTIVE MULTI-CENTER COHORT STUDY – CANCER-CRT STUDY L. Girardi1|2, W. Ageno3, L. Bertù1, C. Lodigiani4, L.A. Ciuffini4, M.C. Vedovati5, C. Becattini5, A. Sammarco6, G. Camporese6, G. Cuni1|7, C. Ambaglio7, M.P. Donadini1 | 1Research Center on Thromboembolic Diseases and Antithrombotic Treatment, Department of Medicine and Surgery, University of Insubria, Varese, Italy; 2Department of Medicine, The Ottawa Hospital Research Institute, University of Ottawa, Ontario, Canada; 3Department of Medicine, University of Padua, Padova, Italy; 4Center for Thrombosis and Hemorrhagic Diseases, IRCCS Humanitas Research Hospital, Rozzano, Milano, Italy; 5Internal and Cardiovascular Medicine-Stroke Unit, University of Perugia, Perugia, Italy; 6Clinica Medica 1, Department of Medicine, DIMED, Padova University Hospital, Padova, Italy; 7Immunohematology and Transfusion Medicine, Department of Transfusion Medicine and Hematology, ASST Papa Giovanni XXIII, Bergamo, Italy
6PDF: 2 -
PO43 | Extended treatment with reduced dose of direct oral anticoagulants in patients with venous thromboembolism: a retrospective study A. Pannunzio1, E. Valeriani1, I.M. Palumbo1, D. Menichelli1, T. Brogi2, S. Marucci2, D. Pastori2, P. Pignatelli2 | 1Department of General Surgery and Surgical Specialty, Sapienza University of Roma; 2Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Roma, Italy
649PDF: 27 -
CO035 | THE ROLE OF INFLAMMATORY BIOMARKERS IN IMMUNE THROMBOTIC THROMBOCYTOPENIC PURPURA F. Schieppati1|2, S. Bolognini1|2, C. Ticozzi1, O.C. Cretu1, P. Gomez-Rosas1|3, M. D’Adda4, V. Cancelli4, C. Ambaglio1, E. Galimberti1, L. Barcella1, A. Falanga1|2, M. Marchetti1|2 | 1Immunohematology and Transfusion Medicine, Department of Transfusion Medicine and Hematology, ERN-EuroBloodNet - European Reference Network in Rare Hematological Diseases, ASST Papa Giovanni XXIII, Bergamo, Italy; 2School of Medicine and Surgery, University of Milano-Bicocca, Milano, Italy; 3Maastricht University Medical Center, Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands; 4Hematology, Hospital Spedali Civili di Brescia, Brescia, Italy
7PDF: 2 -
PO118 | VARIATION OF EGFR IN PATIENT IN DOACS THERAPY S. Vivolo, C. Gagliardi, A. Ciampa | U.O.S.D. Centro Emostasi Aorn S. G. Moscati Avellino, Italy
2PDF: 2 -
CO059 | EXTRACELLULAR VESICLES AS BIOMARKERS IN FAMILIAL HYPERCHOLESTEROLEMIAS TREATED WITH EVINACUMAB C. Samà1, A. Benetti1, M.G. Lupo2, M. Biolo1, C. Portinari1, S. Zambon1, A. Zambon1, N. Ferri2, C.M. Radu1, P. Simioni1 | 1First Chair of Internal Medicine and Thrombotic and Haemorrhagic Diseases Unit, Department of Medicine, Padova University Hospital, Padova, Italy; 2Department of Medicine, Padova University Hospital, Padova, Italy
7PDF: 2 -
PO30 | Acquired angioedema associated with B-non Hodgkin lymphoma: a case report A. Pozzi, G. Rosati, S. Pizzimenti, M. Padrini, S. Laurenti, G. Ferrari, R. M. Medici, C. Barale, I. Russo, A. Morotti | Univeristy of Turin, AUO San Luigi Gonzaga, Orbassano (TO), Italy
575PDF: 30 -
CO-07 | ITALIAN RESOURCE USE IN MILD HEMOPHILIA A AND TYPE 1 VON WILLEBRAND DISEASE A. Gringeri1|2, G.C. Castaman3 | 1Fondazione Charta, Milano, Italy; 2Centro di Sanità Solidale, Lucca, Italy; 3Centre for Bleeding Disorders and Coagulation, Careggi University Hospital, Firenze, Italy
69PDF: 14 -
CO078 | METABOLOMIC AND LIPOPROTEOMIC MODULATION FOLLOWING INCLISIRAN TREATMENT IN DYSLIPIDEMIC PATIENTS J. Patrussi1, A. Vignoli1|2, L. Tenori1|2, A. Sorrentino3, M. Berteotti3|4, E. Lotti4, F. Crudele4, G. Ciarrocca Taranta3, A.A. Rogolino4, G. Barbieri3, A.M. Gori3|4, R. Marcucci3|4 | 1Dep. of Chemistry "Ugo Schiff", University of Florence, Sesto Fiorentino, Italy; 2Magnetic Resonance Center (CERM), University of Florence, Sesto Fiorentino, Italy; 3Dep. of Experimental and Clinical Medicine, University of Florence, Firenze, Italy; 4Azienda Ospedaliero-Universitaria Careggi, Firenze, Italy
8PDF: 2 -
CO074 | WHOLE-BLOOD COAGULATION AND PLATELET DYNAMICS IDENTIFY DIFFERENTIAL PROTHROMBOTIC STATES IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH JAK OR TNFⱭ INHIBITORS L. Spiezia, A. Giollo, L. Di Luozzo, M. Salvato, K. Khalid, R. D’Andrea, A. Benetti, C. Samà, R. Ramonda, P. Simioni | Dipartimento di Medicina, Azienda Osp. Università di Padova, Italy
7PDF: 2 -
PO02 | Pregnancy and delivery in women with hemophilia and carriers are still challenging: a ten years analysis from The Italian Association of Hemophilia Centers (AICE) M. Napolitano1, M. Mattana2, C. Cammarata1, M. Leotta3, S. Linari4, M.E. Mancuso5, G. F. Rivolta6, C. Santoro7, L. Valdrè8, R.C. Santoro3, S. Siragusa1 | 1Department of Health Promotion, Mother and Child Care, Internal Medicine and Med, Palermo; University of Palermo, Italy; 2Department of Precision Medicine in Medical, Surgical and Critical Care “Me. Pre. Cc”, University of Palermo; 3Hemostasis and Thrombosis Unit, Azienda Ospedaliera Universitaria Dulbecco, Catanzaro; 4Center for Bleeding Disorders, Careggi University Hospital, Firenze; 5Center for Thrombosis and Hemorrhagic Diseases, IRCCS Humanitas Research Hospital, Rozzano, Milan; 6Regional Reference Center for the Treatment of Congenital Hemorrhagic Diseases, Parma University Hospital, Parma; 7Hematology, University Hospital Policlinico Umberto I, Roma; 8Inherited Bleeding Disorders Unit, IRCCS AOUBO, Bologna, Italy
689PDF: 19 -
PO53 | PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF REGN7508CAT FOR PRIMARY PROPHYLAXIS OF CANCER-ASSOCIATED THROMBOSIS FOR PARTICIPANTS WITH SOLID TUMORS UNDERGOING CANCER TREATMENT (ROXI-CAT-I) J. Zwicker1, M. P. O’Brien2, M. Carrier3, J. Connors4, A. Falanga5, A. Manzano6, R. Mcbane7, Y.Y. Janjigian1, G. O’Kane8, M. Onisko2, J. Kaplan2, A.P. Kithcart2, D.E. Gutstein2, A. Khorana9, M. F. Walsh2 | 1Memorial Sloan Kettering Cancer Center, New York, USA; 2Regeneron Pharmaceuticals, Inc. , Tarrytown, NY, USA; 3University of Ottawa, Ottawa, ON, Canada; 4Harvard Medical School, Boston, MA, USA; 5Hospital Papa Giovanni XXIII, Bergamo, Italy; 6Hospital Universitario 12 de Octubre, Madrid, Spain; 7Mayo Clinic, Rochester, MN, USA; 8St. Vincent's University Hospital and School of Medicine, University College Dublin, Dublin, Ireland; 9James P. Wilmot Cancer Center and the Department of Medicine, University of Rochester, Rochester, NY, USA
504PDF: 123 -
PO40 | Management of paediatric patients affected by mild factor VII deficiency undergoing surgery B. Borsellino1,2, B. Pollio1, I. Ricca1, R. Albiani1, T. Martini1 | 1Haemophilia Centre, Immune-Haematology and Transfusion Medicine, University Hospital “Città della Salute e della Scienza”, Turin; 2Department of Biomedicine and Prevention, PhD in Immunology, Molecular Medicine and Applied Biotechnology, University of Roma Tor Vergata, Roma, Italy
564PDF: 12 -
PO65 | Utilization of emicizumab in acquired hemophilia A: a case report C. Caputo, P. Conca, I.L. Calcaterra, E. Cimino, M. Romeo, M. Aversano, E. Franco, C. De Luca, G. D’errico, L. Jr Valletta, M. Di Minno, A. Tufano | Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy
618PDF: 26 -
CO043 | LONG TERM TREATMENT WITH VITAMIN K ANTAGONIST IN PEDIATRIC PATIENTS WITH PROSTHETIC HEART VALVE: THE BERGAMO EXPERIENCE T. Zollner1, C. Ambaglio1, F. Duca2, G. Cuni1, E. Galimberti1, O.C. Cretu1, F. Schieppati1, F. Zunino1, V. Brusegan1, M. Marchetti1, A. Falanga1|2, L. Barcella1 | 1Immunohematology and Transfusion Medicine, Department of Transfusion Medicine and Hematology, ERN-EuroBloodNet - European Reference Network in Rare Hematological Diseases, ASST Papa Giovanni XXIII, Bergamo, Italy; 2School of Medicine and Surgery, University of Milano-Bicocca, Milano, Italy
8PDF: 2 -
PO49 | Use of emicizumab in two patients with acquired hemophilia A: a new therapeutic approach S. Sorella, J. Micozzi, E. Baldacci, M. Biglietto, R. Mormile, A. Chistolini, R. Ciciani, L. Torrieri, N. Zhdanovskaya, M. Lorenzon, A. Delli Paoli, S. Ligia, C. Santoro | Hematology, Department of Translational and Precision Medicine, Policlinico Umberto I, Sapienza University of Roma, Italy
658PDF: 25 -
PO85 | Acute retinal ischemia in hemoglobin SC disease: a case report and review of the literature G. Bogoni1, A. Bertomoro1, E. Cosi1, M.T. Sartori1, R. Colombatti2, G. Reggiani2, M.P. Boaro2, I. Bertozzi1, P. Simioni1 | 1Clinica Medica 1, Dipartimento di Medicina DIMED, Università degli Studi di Padova; 2Clinica di Onco-Ematologia Pediatrica, Università degli Studi di Padova, Italy
688PDF: 15 -
-
PO16 | Antithrombotic treatment and outcomes in retinal vein occlusion: a retrospective cohort study and comparison with historical group S.A. Malerba1,2, M.T. Sartori1, G. Libralon1, C. Dalla Porta1, P. Simioni1 | 1First Medical Clinic, Department of medicine- DIMED, Università degli Studi di Padova; 2Medicina Generale, Ospedale dell’Angelo, Mestre, Italy
607PDF: 11 -
PO002 | VENOUS THROMBOEMBOLISM IN PATIENTS WITH FACTOR VII DEFICIENCY: A CASE SERIES AND REVIEW OF THE LITERATURE BM. Roccon1, MI. Tassoni1, G. Quintavalle1, F. Riccardi1, A. Matichecchia1, GF. Rivolta1, M. Lombardi3, R. Rossi2, A. Benegiamo2, A. Tagliaferri1, A. Coppola1 | 1SSD Centro Hub Emofilia e Malattie Emorragiche Congenite, Azienda Ospedaliero-Universitaria di Parma, Italy; 2Lab. di Coagulazione, UOC Diagnostica Ematochimica, Azienda Ospedaliero-Universitaria di Parma, Italy; 3Centro Emostasi, UOC Medicina Interna ad indirizzo angiologico e coagulativo, Azienda Ospedaliero-Universitaria di Parma, Italy
7PDF: 1 -
PO45 | Routine prophylaxis with PD-FX concentrate in severe inherited FX deficiency: a case report S. Linari, L. Pieri, M. Attanasio, F. Salvianti, M. Coppo, E. Grisanti, F. Demartis, R. Fjerza, G. Castaman | Centre for Bleeding Disorders and Coagulation, Azienda Ospedaliera Universitaria Careggi, Firenze, Italy
619PDF: 20 -
PO37 | Single centre experience on anticoagulation in carriers of non-mild inherited thrombophilia: direct oral anticoagulants (DOAC) efficacy and safety M. D’uva1,2, G. La Barba1, G. Montanaro1, M. Di Ianni1,2, P. Ranalli1,2 | 1Hematology Unit, S. Spirito Hospital, Pescara; 2Department of Medicine and Aging Sciences, D’Annunzio University, Chieti, Italy
644PDF: 21 -
PO048 | EFFICACY OF RITUXIMAB TREATMENT IN A CASE OF A RELAPSED AND REFRACTORY ACQUIRED VON WILLEBRAND DISEASE SECONDARY TO PRIMARY CUTANEOUS MARGINAL ZONE B-CELL LYMPHOMA L. Gurgoglione1, F. Saladino2, E. Morsia2, N. Viola3, S. Rupoli1, A. Poloni2 | 1Clinical Hematology, AOU delle Marche, Ancona, Italy; 2Università Politecnica delle Marche, Ancona, Italy; 3Clinical Immulogy, AOU delle Marche, Ancona, Italy
7PDF: 2 -
CO-19 | A CASE OF LOSS OF EFFICACY OF EMICIZUMAB AFTER 6 YEARS OF REGULAR USE M.R. Fasulo1, I. Quaglia1, A. Colombo1, C. Lodigiani1, M.E. Mancuso1|2 | 1Center for Thrombosis and Hemorrhagic Diseases, IRCCS Humanitas Research Hospital, Rozzano, Milano, Italy; 2Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milano, Italy
24PDF: 14 -
PO70 | Clinical safety and monitoring of apixaban combined with tacrolimus and everolimus in kidney transplant patients: a prospective study S. Guglielmo1, E. De Bon2, L. Scarano1, R. Fabris1, E. Pierobon3, S. Barbar2 | 1Internal Medicine, Department of Medicine, Azienda ULSS 6 Euganea, Cittadella; 2Thrombotic and Hemorrhagic Disorders Unit, Department of Medicine, Azienda ULSS 6 Euganea, Cittadella; 3Nephrology and Dialysis Unit, Azienda ULSS 6 Euganea, Cittadella and Camposampiero, Padova, Italy
632PDF: 25 -
PO151 | HIGH-RISK SURGERY IN SEVERE HAEMOPHILIA B: PERIOPERATIVE MANAGEMENT WITH ALBUTREPENONACOG ALFA F. Ricci, M. De Siati, M. Comand, F.G. Perretta, A. Ferretti, M. Basso, E. De Candia, R. De Cristofaro | Fondazione Policlinico Universitario Gemelli IRCCS, Roma, Italy
7PDF: 2 -
BEST-02 | PERIOPERATIVE BLEEDING IN CHILDREN WITH LOW VON WILLEBRAND FACTOR UNDERGOING ADENOID AND TONSIL SURGERY: A 15-YEAR SINGLE-CENTER EXPERIENCE T. Martini1, B. Borsellino1|2, B. Pollio1 | 1Haemophilia Centre, Immune-Haematology and Transfusion Medicine, University Hospital “Città della Salute e della Scienza”, Torino, Italy; 2Department of Biomedicine and Prevention, PhD in Immunology, Molecular Medicine and Applied Biotechnology, University of Rome Tor Vergata, Roma, Italy
74PDF: 18 -
CO-81 | DIGITAL NETWORKING FOR ACQUIRED HEMOPHILIA A: A REGION-WIDE CARE PATHWAY FROM DIAGNOSIS TO FOLLOW-UP M. Mattana1, M.F. Mansueto2, S. Raso1, S. Siragusa2|3, R. Tomasello1, M. Napolitano1|3 | 1A.O.O.R. Villa Sofia Cervello P.O. Cervello-UOC di Ematologia per le Malattie Rare del Sangue e degli Organi Ematopoietici, Palermo, Italy; 2UOC Ematologia Policlinico P.Giaccone Palermo, Italy; 3Dipartimento Promozione della Salute, Materno-Infantile, di Medicina Interna e Specialistica di Eccellenza(PROMISE), Università degli studi di Palermo, Italy
25PDF: 13 -
PO037 | TEMPO: A MOBILE HEALTH APPLICATION FOR PERSONALIZED MANAGEMENT OF HEMOPHILIA R. Gualtierotti1|2, F. Franco3, L. Bedogni4, M. Fassi1, A.A Giachi1, S. Mascetti5, M. Manzoni5, F. Poggi6, M. Pellegrini6, C. Suffritti1, F. Peyvandi1|2 | 1Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milano, Italy; 2Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milano, Italy; 3Department of Physics, Informatics and Mathematics (FIM), University of Modena and Reggio Emilia, Modena, Italy; 4Department of Sciences and Method for Engineering (DISMI), University of Modena and Reggio Emilia, Modena, Italy; 5Department of Computer Science, Università degli Studi di Milano, Milano, Italy; 6Institute for Cognitive Sciences and Technologies (ISTC), National Research Council (CNR), Bologna, Italy
7PDF: 2 -
The evolving landscape of gene therapy for congenital severe hemophilia: a 2024 state of the art
2083PDF: 359SUPPLEMENTARY MATERIAL: 217 -
CO33 | Acquired hemophilia A in Liguria, Italy: what six years of data reveal C. Vernarecci1, A. C. Molinari1, P. Ballarino2, M. Caiti2, E. Cenni2, P. Moscatelli2, L. Banov1 | 1IRCCS Istituto Giannina Gaslini, Genova; 2IRCCS Policlinico San Martino, Genova, Italy
609PDF: 30 -
PO05 | Intensive FVIII replacement in haemophilia patients with hypertrophic synovium: a randomized study I.L. Calcaterra1, E. Baldacci2, R. Marino3, F. Valeri4, R.C. Santoro5, G. Pasta6, C. Martinoli7, M. Di Minno1 | 1Department of Clinical Medicine and Surgery, Federico II University, Naples; 2Haematology, University Hospital Policlinico Umberto I, Roma; 3Haemophilia Center and thrombosis, Policlinico, Bari; 4Regional Centre for Haemorrhagic and Thrombotic Diseases, AOU Città Della Salute e Della Scienza; Turin; 5Centre for Hemorrhagic and Thrombotic Disorders, Pugliese Ciaccio Hospital, Catanzaro; 6Fondazione IRCCS San Matteo Hospital, Pavia; 7Department of Health Science DISSAL, University of Genoa, Unit of Radiology and IRCCS San Martino Hospital, Genoa, Italy
593PDF: 17 -
PO069 | PERIOPERATIVE CHALLENGES IN ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA DURING CAPLACIZUMAB TREATMENT J. Agnelli Giacchello1, P. Sciancalepore1, N.F. Trincheri2, L. Contino1, M. Ladetto3, R.M. Santi1 | 1SSD Emostasi e trombosi e malattie rare; 2SC Laboratorio Analisi; 3SCDU Ematologia, AOU SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
6PDF: 2 -
CO029 | REAL WORLD EVALUATION OF A NOVEL PATIENT CENTERED OUTCOME INDICATOR TO SUPPORT VALUE BASED HEALTHCARE DECISION-MAKING IN HEMOPHILIA A IN ITALY: THE HEMPROVE NON-INTERVENTIONAL STUDY G. Castaman1, C. Santoro2, E. Ferri Grazzi3, S. Bendinelli4, R. Perrone4, C. Lainez Diaz4, P.A. Cortesi5, M.N.D. Di Minno6 | 1Dep. of Oncology, Centre for Bleeding Disorders and Coagulation, Careggi Univ. Hosp., Firenze, Italy; 2Hematology, Dep. of Translational and Precision Medicine, Sapienza University of Roma, Italy; 3FedEmo, Milano, Italy; 4Roche S.p.A. Italy, Monza, Italy; 5CESP, Univ. of Milano-Bicocca, Monza, Italy; 6Dep. of Clinical Medicine and Surgery, Regional Reference Center for Coagulation Disorders, Federico II Univ., Napoli, Italy
10PDF: 2 -
PO40 | RADAR, UK-MRA MYELOMA XV - COMPARING MRD-GUIDED TREATMENT ESCALATION AND DE-ESCALATION STRATEGIES IN PATIENTS WITH NEWLY DIAGNOSED MYELOMA SUITABLE FOR STEM CELL TRANSPLANTATION: THROMBOPROPHYLAXIS SUBGROUP STUDY PROTOCOL Z. Sayar, on behalf of the RADAR Investigators | Whittington Health NHS Trust and Royal Free Hospital, London, UK
479PDF: 109 -
PO097 | DETERMINANTS OF PLATELET COUNT IN A LARGE SINGLE TERTIARY CARE COHORT: IMPACT OF AGE, SEX, PLATELET REACTIVITY, CARDIOVASCULAR RISK FACTORS AND ANTIPLATELET THERAPY S. De Corci, N. Manganello, E. Schiera, S. Terracina, A. Di Battista, F.M. Pulcinelli | Experimental Medicine, Sapienza University of Rome, Italy
7PDF: 1 -
CO102 | VARIABILITY IN ANTIPHOSPHOLIPID ANTIBODY TESTING AND TREATMENT STRATEGIES IN OBSTETRIC ANTIPHOSPHOLIPID SYNDROME: RESULTS FROM THE OAPS-CARE SURVEY, ON BEHALF OF THE EUROPEAN FORUM ON ANTIPHOSPHOLIPID ANTIBODIES A. Hoxha1|2, E. Esteve-Valverde3|4, G. Gobbo1|2, F. Miró-Mur4, M. Radin5, S. De Carolis6, C. Trilla7|8|9|10, A. Tincani11|12, R. Cervera13|14, J. Alijotas-Reig3|15|16 | 1Department of Medicine - DIMED, University of Padua, Padova, Italy; 2Internal Medicine Unit, Thrombosis and Bleeding Disorder, University Hospital of Padua, Padova, Italy; 3Systemic Autoimmune Diseases Unit. Department of Internal Medicine, Hospital Sant Camil, Consorci Sanitari Alt-Penedes-Garraf, Sant Pere de Ribas, Barcelona, Spain; 4Systemic Autoimmune Disease Research Unit. Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain; 5Center of Research of Immunopathology and Rare Diseases - Coordinating Center of Piemonte and Valle d'Aosta Network for Rare Diseases, SCDU Nephrology and Dialysis, School of Specialization of Clinical Pathology, Department of Clinical and Biological Sciences, S. Giovanni Bosco Hospital, University of Turin, Torino, Italy; 6Fondazione Policlinico Universitario A. Gemelli IRCCS, Dipartimento di Scienze per la salute della Donna e del Bambino e di Sanità Pubblica, Roma, Italy; 7Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; 8Universitat Autònoma de Barcelona, Barcelona, Spain; 9Spanish Network in Maternal, Neonatal, Child and Developmental Health Research (RICORS-SAMID, RD24/0013/0001), Instituto de Salud Carlos III, 28040 Madrid, Spain; 10Women and Perinatal Health Research Group, Institut de Recerca (IR SANT PAU), Sant Quintí 77-79, 08041 Barcelona, Spain; 11Rheumatology and Clinical Immunology Unit - ERN ReCONNET, ASST Spedali Civili, Brescia, Italy; 12Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy; 13Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, Barcelona, Catalonia, Spain; 14August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Catalonia, Spain; 15Department of Medicine. Universitat Autonoma de Barcelona, Barcelona, Spain; 16Systemic Autoimmune Disease Unit, Department of Internal Medicine, Vall d’Hebron University Hospital, Barcelona, Spain
8PDF: 2 -
CO-78 | REAL-WORLD MANAGEMENT OF ACQUIRED HEMOPHILIA A: FOCUS ON RECOMBINANT PORCINE FVIII AS FIRST-LINE HEMOSTATIC TREATMENT AND LONG-TERM OUTCOMES M. Leotta, A. Strangio, A. Ierardi, R.C. Santoro | Hemophilia, Hemostasis and Thrombosis Centre, Azienda Ospedaliero Universitaria Renato Dulbecco, Catanzaro, Italy
22PDF: 15 -
PO115 | AL AMYLOIDOSIS IN A PATIENT WITH SEVERE HEMOPHILIA A AND INHIBITORS WHO HAD A MONOZYGOTIC TWIN: SAME GENES, DIFFERENT OUTCOMES M. Biglietto, S. Sorella, S. Ligia, C. Andriola, R. Mormile, E. Baldacci, A. Chistolini, C. Santoro | Sapienza, University of Rome, Italy
6PDF: 2 -
CO-22 | CLINICAL FEATURES IN PATIENTS WITH NON-SEVERE HEMOPHILIA A: THE DISCOVERY SCORE PROPOSAL FOR PROPHYLAXIS PRESCRIPTION M.N.D. Di Minno1, E. Baldacci2, C. Biasoli3, A. Borchiellini4, F. Daniele5, P. Di Gregorio6, C. Gorio7, G. Malcangi8, E. Marchesini9, I. Ricca10, R. Santoro11, S. Siragusa12, M.R. Villa13, E. Zanon14, A. Tagliaferri15, A. Coppola15 | 1Hub Centre for Thrombotic and Hemorrhagic Disorders, Federico II University Hospital, Napoli, Italy; 2Haematology, University Hospital Policlinico Umberto I, Roma, Italy; 3Interdepartmental Simple Structure for the Management of Hemorrhagic and Thromboembolic Diseases, M. Bufalini Hospital, Cesena, Italy; 4Regional Centre for Hemorrhagic and Thrombotic Diseases, AOU Città della Salute e della Scienza, Torino, Italy; 5Haemostasis and Thrombosis Service, Ospedale Civile dell'Annunziata, Cosenza, Italy; 6Transfusion Medicine Department, "SS. Annunziata" Hospital, Chieti, Italy; 7Pediatric Onco-Hematology Unit, Children's Hospital, ASST-Spedali Civili, Brescia, Italy; 8Haemophilia and Thrombosis Center, University Hospital Policlinico-Giovanni XXIII, Bari, Italy; 9Hemophilia Centre, SC Vascular and Emergency Department, University of Perugia, Italy; 10Centro Emofilia, Città della Salute e della Scienza, Torino, Italy; 11Hemostasis and Thrombosis Unit, Azienda Ospedaliero Universitaria Dulbecco, Catanzaro, Italy; 12Centro di Riferimento Regionale per le Emocoagulopatie Congenite, Palermo, Italy; 13Hematology Unit, Ospedale Santa Maria di Loreto, Napoli, Italy; 14Hemophilia and Thrombosis Center, University Hospital of Padua, Italy; 15Hemophilia and Thrombosis Center, Azienda Ospedaliera di Parma, Italy
33PDF: 11 -
PO093 | HOW LONG IS TOO LONG? A CASE OF SEVERE PERSISTENT THROMBOCYTOPENIA B. Clerici1|2, C. Ghali2, M. Scavone2, A. Fioretti2, M. Perego1, C. Mondini1|2, E. Fiorini1, L. Catarini1, C. Pescia3, S. Caberlon1, U. Gianelli2|3, G.M. Podda1|2 | 1S.C. Medicina Generale SP, Ospedale San Paolo, ASST Santi Paolo e Carlo, Milano, Italy; 2Dipartimento di Scienze della Salute (DISS), Università degli Studi di Milano, Milano, Italy; 3S.C. Anatomia Patologica, Ospedale San Paolo, ASST Santi Paolo e Carlo, Milano, Italy
6PDF: 2 -
CO45 | Role of urinary 11-dehydro-thromboxane B2 as a predictor of preeclampsia in pregnant high-risk women on low-dose aspirin treatment P.G.M. Simeone1, R. Liani1, M. Alfonsetti1, A. Ricci1, V. Cianci1, S. Zeeba2, M. Molino3, S. Palma2, R. Malizia4, M. Luongo4, A. Di Castelnuovo5, F. Cipollone1, F. D’antonio6, F. Ricci2, G. Renda2, F. Santilli1 | 1Department of Medicine and Aging Sciences, Center for Advanced Studies and Technology, University of Chieti; 2Department of Neuroscience, Imaging and Clinical Sciences, G D’Annunzio University of Chieti-Pescara, Chieti; University Cardiology Division, Heart Department, Policlinico SS Annunziata, Chieti; 3Clinical Pathology of Chieti University Hospital; 4Immunotransfusion Service, Clinical Haematology of Chieti University Hospital, Chieti; 5Mediterranea Cardiocentro, Napoli; 6Centre for Fetal Care and High-Risk Pregnancy, Department of Obstetrics and Gynecology, University of Chieti, Italy
617PDF: 13 -
CO-33 | REAL-WORLD EXPERIENCE WITH MARSTACIMAB PROPHYLAXIS IN SEVERE HEMOPHILIA A WITHOUT INHIBITORS AND ADVANCED HEMOPHILIC ARTHROPATHY A. Casson1, I. Ricca1, A. Barchieri1, G. Guido1, M. Tucciarone1, P. Ocello1, C. Francisco2, P. Abrate2, G. Delios1 | 1Centro Malattie Trombotiche ed Emorragiche - SC Servizio Trasfusionale ASL TO4, Ivrea, Torino, Italy; 2SC Farmacia Ospedaliera ASL TO4, Ivrea, Torino, Italy
25PDF: 11 -
PO114 | A CASE OF ACQUIRED HEMOPHILIA AFTER TAVI AND CORONARY ANGIOPLASTY IN PATIENT WITH ATRIAL FIBRILLATION AND MULTIPLES CARDIOVASCULAR RISK FACTORS – THE ART AND SCIENCE OF THERAPEUTIC CONFLICT M.M. Poggi1, C. Tamburini2, M. Littera2, M. Mazzetti2 | 1SOC Medicina 1, Nuovo Ospedale Prato, Prato, Italy; 2SOD Medicina Interna Interdisciplinare, Azienda Ospedaliera Universitaria Careggi, Firenze, Italy
7PDF: 2 -
CO39 | Artificial intelligence in hemophilia management: challenging the need for experts G. Sottilotta1, D. Megalizzi1, F. Luise2 | 1UOSD Microcitemie - Emostasi e Trombosi. Grande Ospedale Metropolitano Bianchi-Melacrino-Morelli, Reggio Calabria; 2Laboratorio Analisi, Grande Ospedale Metropolitano Bianchi-Melacrino-Morelli, Reggio Calabria, Italy
608PDF: 14 -
PO125 | ROMIPLOSTIM FOR CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA IN ADVANCED SOLID TUMORS: A SINGLE-CENTER EXPERIENCE G. Giustini1, A. Baffioni1, C. Giubbilei1, A.M. Vannucchi2, V. Carrai3 | 1SOD Ematologia, Università degli studi di Firenze, Italy; 2Center for Research and Innovation of Myeloproliferative Neoplasms, SOD Ematologia, AOU Careggi, Università degli studi di Firenze, Italy; 3SOD Ematologia, Dipartimento di Oncologia, AOU Careggi, Firenze, Italy
2PDF: 2 -
CO049 | RANDOMIZED CONTROLLED TRIAL TO IDENTIFY THE OPTIMAL SCHEME OF HEPARIN FOR TREATMENT OF DEEP VEIN THROMBOSIS IN PREGNANCY E. Grandone1|3, E. Antonucci2, A. de Laurenzo1, L. Latino1, M. Mastroianno1, G. Tiscia1, M. Margaglione3, P. Prandoni2 | 1IRCCS Casa Sollievo della Sofferenza, S.Giovanni Rotondo, Italy; 2Fondazione Arianna, Italy; 3Università di Foggia, Italy
9PDF: 2 -
PO14 | Searching for safer rescue immunosuppressive therapy protocols in acquired hemophilia A: two case reports G. Quintavalle1, I.M. Tassoni1, B.M. Roccon1, G. Lucchini2, F. Magalini2, M. Zardo2, R. Rossi3, C. Cattabiani3, A. Tagliaferri1, A. Coppola1 | 1SSD Centro HUB Emofilia e MEC; 2UOS Medicina Interna e Reumatologia; 3UO Diagnostica Ematochimica, Azienda Ospedaliero Universitaria, Parma, Italy
549PDF: 19 -
OC13 | VON WILLEBRAND FACTOR PREDICTS POOR OUTCOME IN PANCREATIC CANCER AND MEDIATES TUMOR-ENDOTHELIUM INTERACTIONS FACILITATING METASTASIS B. Ünlü1, Z. Zhao1, N. Joshi1, S. De1, A. Chion1, I. Schoen1, J. O’Donnell1, M. Flick2, M. Fishel3|4, J. O’Sullivan1 | 1School of Pharmacy and Biomolecular Sciences, Irish Centre for Vascular Biology, Royal College of Surgeons in Ireland, Dublin, Ireland; 2UNC Blood Research Center, University of North Carolina at Chapel Hill, Chapel Hill, USA; 3IU Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, IN, USA; 4Department of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN, USA
474PDF: 95 -
CO01 | Statin therapy for the prevention of venous thromboembolism in cancer patients: a systematic review and meta-analysis F. Catalani, R. Del Giorno, R. Canevascini, W. Ageno, L. Gabutti, G. Prouse, L. Giovannacci | Ospedale Regionale di Bellinzona, Switzerland.
697PDF: 14 -
PO82 | Retrospective application of the TH2 score in a multicenter cohort of ITP patients: a reliable predictive tool or a score in need of refinement? C. Giubbilei1, M. Defina2, S. Rosati3, M. Rocco3, A. Votto4, F. Simonetti5, F. Paoletti6, V. Carrai1 | 1Hematology Unit, AOU Careggi; 2Hematology unit AOU Senese; 3Hematology Unit Azienda Sanitaria Toscana Centro; 4Hematology Unit, AOU Pisana; 5Hematology Unit, Ospedale Versilia; 6Hematology Unit, Azienda Sanitaria Nord Ovest, Italy
564PDF: 16 -
PO161 | A REGIONAL DIGITAL NETWORK FOR THE MANAGEMENT OF ACQUIRED HEMOPHILIA A: A MODEL FOR INTEGRATED CARE M. Mattana1, S. Raso1, R. Tomasello1, MF. Mansueto1, C. Cammarata2, S. Siragusa3, M. Napolitano1|3 | 1A.O.O.R. Villa Sofia Cervello P.O. Cervello-UOC di Ematologia per le Malattie Rare del Sangue e degli Organi Ematopoietici, Italy; 2PO Sant'Elia, Caltanissetta, Italy; 3Dipartimento di Promozione della Salute, Materno-Infantile, Medicina Interna e Specialistica di Eccellenza (ProMISE), Università degli Studi di Palermo, Italy
5PDF: 2 -
CO-71 | ACQUIRED FACTOR XIII DEFICIENCY IN A PATIENT POST-CAR-T THERAPY FOR NON-HODGKIN LYMPHOMA: A CASE REPORT A. Strangio, M. Leotta, A. Ierardi, R.C. Santoro | Hemophilia, Hemostasis and Thrombosis Unit, Azienda Ospedaliero Universitaria Renato Dulbecco, Catanzaro, Italy
26PDF: 17 -
PO12 | Characterisation and real word clinical data of HEM006, a newly formulated intranasal spray desmopressin (DDAVP) to address a global treatment gap G. De Giorgi1, A. Gringeri2, R. Franceschini1, A. Koganti3 | 1Hemorare Srl, Italy; 2Fondazione Charta, Milan, Italy; 3Quenya LLC, USA
570PDF: 12 -
PO64 | MANAGEMENT OF BLEEDING RISK IN PATIENTS WITH HEPATOCELLULAR CARCINOMA RECEIVING SYSTEMIC THERAPY: A SURVEY OF CLINICAL PRACTICE T. Van Broeckhoven1|9, E. Van Gansewinkel5|10, J. De Bruijne2, F. Eskens3, D. De Groot4, K. Hermans5, N. Mohammad6, F. Van Vilsteren7, C. Verslype8, W. Moris9, M. Roest10, B. De Laat10 , J. De Vos-Geelen5, M. Kramer1|9 | 1Department of Gastroenterology and Hepatology, GROW – Research Institute for Oncology and Reproduction, Maastricht University Medical Center, Maastricht, The Netherlands; 2Department of Gastroenterology & Hepatology, Utrecht University, University Medical Center Utrecht, The Netherlands; 3Department of Medical Oncology, Erasmus Medical Centre, Rotterdam, the Netherlands; 4Department of Medical Oncology, University Medical Centre Groningen, University of Groningen, the Netherlands; 5Department of Internal Medicine, Division of Medical Oncology, GROW – Research Institute for Oncology & Reproduction, Maastricht University Medical Center, Maastricht, The Netherlands; 6Department of Medical Oncology, University Medical Centre Utrecht, Utrecht University, Utrecht, the Netherlands; 7Department of Gastroenterology and Hepatology, University Medical Centre Groningen, Groningen, The Netherlands; 8Digestive Oncology, University Hospitals Leuven, Belgium; 9Department of Gastroenterology and Hepatology, Maastricht University Medical Center, Maastricht, The Netherlands; 10Department of Functional Coagulation, Synapse Research Institute, Maastricht, The Netherlands, on behalf of the Dutch Hepatocellular & Cholangiocarcinoma Group
440PDF: 96 -
PO89 | Apixaban for secondary prevention of venous thromboembolism in hemodialysis patients: pharmacokinetic profile and safety outcomes S. Guglielmo1, E. De Bon2, L. Scarano1, R. Fabris1, E. Pierobon3, S. Barbar2 | 1Internal Medicine, Department of Medicine; 2Thrombotic and Hemorrhagic Disorders Unit, Department of Medicine; 3Nephrology and Dialysis Unit, Azienda ULSS 6 Euganea, Cittadella and Camposampiero, Padua, Italy
844PDF: 14 -
PO011 | A TWO CENTERS REAL-WORLD EXPERIENCE WITH ANTI-XA DIRECT ORAL ANTICOAGULANTS IN CANCER PATIENTS WITH UNUSUAL SITE VEIN THROMBOSIS U. Mazzarelli1, L. Agrelli1, A. Cirillo1, C. Caputo2, M. Romano2, R. Russo2, R. Guarrasi3, M. Triggiani1, A. Tufano2, A. Guida4 | 1Dipartimento di Medicina Interna, Università degli studi di Salerno, Italy; 2Dipartimento di Medicina Interna, Università degli studi di Napoli Federico II, Italy; 3UOC Clinica Oncologica; 4Centro per le malattie emorragiche congenite e malattie trombotiche AOU San Giovanni di Dio e Ruggi d'Aragona Salerno, Italy
6PDF: 2 -
CO037 | PERFORMANCE OF A QUALITATIVE POINT-OF-CARE TEST IN PATIENTS EXPERIENCING ACUTE THROMBOEMBOLIC OR MAJOR BLEEDING EVENTS TREATED WITH DOACs: THE T-BLEEDOAC MULTICENTER PROSPECTIVE COHORT STUDY M. Vedovati1, G. Pepe2, S. Vanni3, E. Campello4, F. Morello5, S. Beccatini1, D. Giudici1, F. Lucarini2, L. Parmeggiani3, G. Fabiani3, P. Simioni4, M. Santoro5, P. Nazerian6, M. Mosconi1, C. Becattini1 | 1University of Perugia, Perugia, Italy; 2Versilia Hospital, Tuscany North West Health System, Lido di Camaiore (LU), Italy; 3Università di Firenze, Firenze, Italy; 4University of Padua, Padova, Italy; 5A.O.U. Città della Salute e della Scienza, Torino, Italy; 6Careggi University Hospital, Firenze, Italy
6PDF: 1 -
PO13 | OUTPATIENT TREATMENT OF VENOUS THROMBOEMBOLISM AND SUBSEQUENT RISK OF CANCER S. Sørensen, D. Farkas, H. Sørensen | Department of Clinical Epidemiology, Aarhus University Hospital and Aarhus University, Aarhus, Denmark
434PDF: 102 -
PO34 | A negative oncologic follow up doesn’t always really mean no cancer: two case report of cancer-associated thrombotic microangiopathy E. Cosi, A. Bertomoro, G. Bogoni, I. Bertozzi, I. Cortella, P. Simioni | Clinica Medica ORI, Azienda Ospedale-Università Padova, DIDAS, Italy
591PDF: 25 -
CO07 | Real word management of anticoagulant therapy in brain metastasis: moving toward a multidisciplinary approach in complex cases E. Lotti1, C. Manneschi2, S. Fancelli2, F. Scolari1, F. Crudele1, D. Poli1, M. Berteotti1, D. Rossini3, S. Pillozzi2, L. Antonuzzo2,3, R. Marcucci1,3 | 1Disease Unit, Careggi University Hospital, Firenze; 2Oncology Unit, Careggi University Hospital, Firenze; <sup>3</sup>Department of Experimental and Clinical Biomedical Sciences, University of Firenze, Italy
619PDF: 20 -
CO105 | THALIDOMIDE FOR RECURRENT GASTROINTESTINAL BLEEDING IN RARE BLEEDING DISORDERS AND VENOUS MALFORMATIONS: A MONOCENTRIC EXPERIENCE M. De Siati1|2, F.G. Perretta1|2, F. Ricci1|2, A. Ferretti1, M. Comand1|2, S. Sorrentino1, L. D’Innocenzo1|2, D. Feliciani2, B. Funaro2, M.E. Riccioni3, A. Gasbarrini2|4, E. De Candia1|2 | 1UOSD Malattie Emorragiche e Trombotiche, Fondazione Policlinico Agostino Gemelli IRCCS, Roma 00168, Italy; 2Department of Translational Medicine and Surgery, Catholic University of the Sacred Heart, Roma, Italy; 3Digestive Endoscopy Unit, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Università Cattolica del Sacro Cuore, Largo Agostino Gemelli, Roma 00168, Italy; 4Department of Medical and Surgical Sciences, Digestive Disease Center, Universitary Policlinic Agostino Gemelli Foundation IRCCS, Roma, Italy
2PDF: 2 -
PO42 | Acquired Von Willebrad syndrome in patients with myeloproliferative syndrome: literature review and single-center experience A. Strangio, M. Leotta, A. Ierardi, R C. Santoro | UO Emofilia, Emostasi e Trombosi, AOU R Dulbecco, Catanzaro, Italy
549PDF: 22 -
CO18 | Relationship between gut permeability and PCSK9 in heterozygous familial hypercholesterolemia V. Castellani1, V. Cammisotto2, F. Baratta2, S. Bartimoccia3, C. Nocella2, L. D’erasmo1, N. Cocomello2, C. Barale4, R. Scicali5, I. Russo4, F. Purrello5, R. Carnevale3, F. Violi2, M. Arca1, P. Pignatelli2 | 1Department of Translational and Precision Medicine, Sapienza University of Roma; 2Department of Clinical, Internal Medicine, Anesthesiology and Cardiovascular Sciences, Sapienza University of Roma; 3Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Roma; 4Department of Clinical and Biological Sciences, University of Turin; 5Department of Clinical and Experimental Medicine, Internal Medicine, University of Catania, Italy
600PDF: 16 -
PO111 | A RARE CASE OF ACUTE PROMYELOCYTIC LEUKAEMIA PRESENTING WITH A PURELY THROMBOTIC DISSEMINATED INTRAVASCULAR COAGULATION PHENOTYPE L. Colavolpe, M. Provisione, L. Appio, S. Tupputi, N. Mumoli | ASST Valle Olona, Busto Arsizio, VA, Italy
7PDF: 2 -
PO045 | FROM PROPHYLAXIS TO ENDOGENOUS CONTROL: A SIX-MONTH REAL-WORLD EXPERIENCE WITH VALOCTOCOGENE ROXAPARVOVEC GENE THERAPY M. Basso1, A. Ferretti1, M. Sacco1, S. Lancellotti1, T. Pirozzi1, L. Di Gennaro1, R. De Cristofaro1|2 | 1Servizio Malattie Emorragiche e Trombotiche, Fondazione Policlinico Universitario Gemelli IRCCS, Italy; 2Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica S. Cuore, Roma, Italy
6PDF: 2 -
CO-80 | EMICIZUMAB PLASMA CONCENTRATIONS AND CLINICAL OUTCOMES IN ACQUIRED HEMOPHILIA A: A REAL-WORLD SINGLE-CENTER EXPERIENCE C. Simion1|2, E. Zanon1|2, C. Bulato1, B. Stocco1|2, F. Righetto1, F. Sartorello1, P. Simioni1|2 | 1First Chair of Internal Medicine and Thrombotic and Haemorrhagic Diseases Unit, Department of Medicine, Padova University Hospital, Italy; 2Hemophilia Center, Padova University Hospital, Italy
25PDF: 13
